SEC Form 4 · accession 0001387131-15-002579
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert B Rothermel
Director
Period of report
Aug 13, 2015
Accepted (ET)
Aug 17, 2015 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 13, 2015 | P | 5,000 | $3.2988 | A | 25,000 | D | |
| Common StockF2 | Aug 14, 2015 | P | 2,000 | $3.3998 | A | 27,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted avergae price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.30, inclusive. The reporting person undertakes to provide to Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.358 to $3.426, inclusive. The reporting person undertakes to provide to Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.